Disney's 'This Is the Way' Blueprint for AI Copyright Survival
Disney didn't just sue— it licensed. And in doing so, carved a Mandalorian path through AI's copyright chaos, leaving copycats like Midjourney in the dust.
Picture this: your client's teams are at war, and you're the unwilling referee. Here's why smart lawyers build firewalls against that mess — before it torches your relationship.
Disney didn't just sue— it licensed. And in doing so, carved a Mandalorian path through AI's copyright chaos, leaving copycats like Midjourney in the dust.
Picture this: a final PTAB decision looming, claims holding firm. Then, bam—ex parte reexam filed 48 hours after a related loss. Welcome to patent warfare's latest cheat code.
Everyone figured GDPR would nail Big Tech's data hoarding. Wrong. Italy just dropped €11.5 million in fines on a gas supplier for old-school tricks like robocalls and ghost contracts.
Imagine your team's laptops in home offices worldwide, buzzing with customer secrets. Here's how encryption turns that vulnerability into ironclad strength.
Everyone thought Bruen would torch gun laws. Rahimi slammed the brakes, demanding history. Now the Court's unpacking who packs heat, what guns, where—and it's a judicial circus.
Over 113 million health records leaked in U.S. breaches last year alone. Now D.C. wants to slam the door on sneaky data collection near clinics—EPIC's cheering, with caveats.
Imagine your breakthrough cooling tech for sun-soaked screens, praised by rivals, licensed out, yet crushed in court. The nexus trap strikes again, exposing patent perils for modular innovations.
You're expecting wild revelations from patent inventor names. Nope – it's a parade of predictable guy-next-door monikers. Dig deeper, though, and the real power shift emerges.
The Federal Circuit just turned PTAB appeals into a high-wire act for patent challengers. One claim amendment, and your standing declaration? Obsolete.
The faith-based AI adoption rush of 2025 crashes into 2026's ROI demands. IP pros without metrics? Budget axes loom.
President Trump's bold EO slaps 100% tariffs on imported patented pharmaceuticals. Drugmakers face a stark choice: move to America or pay up.
A plaintiff's big idea, typed into ChatGPT, just got ruled non-secret by a federal judge. Two fresh cases signal massive risks for anyone whispering trade secrets to generative AI.